Bio-Techne (NASDAQ:TECH) is the target of a major acquisition offer from Merck KGaA for $73 per share, valuing the company at approximately $11.3 billion. Analyst firm William Blair downgraded Bio-Techne's stock to "Market Perform," reflecting limited upside potential given the acquisition price. The proposed deal is under scrutiny, with activist investor involvement preceding the offer and a law firm investigating the fairness of the transaction for public shareholders.Bio-Techne (NASDAQ:TECH) is a U.S. c ...